United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

4 days ago · United Therapeutics believes that xenotransplantation offers a therapeutic alternative to dialysis. “Clearance of our IND for this first-ever clinical trial of a xenokidney represents a significant step forward in our relentless mission to expand the availability of transplantable organs,” said Leigh Peterson, Ph.D., Executive Vice ...

4 days ago · SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 03, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug ...

United Therapeutics Corporation is an American publicly traded biotechnology company [2] and public benefit corporation [3] listed on the NASDAQ under the symbol UTHR. [4][5] It develops novel, life-extending technologies for patients in the areas of …

4 days ago · United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited pigs could provide a viable option for human patients.

3 days ago · United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced full enrollment of the TETON 1 study evaluating the use of Tyv

United Therapeutics is a biotechnology company focused on creating unique products to address the medical needs of patients with chronic illnesses.

United Therapeutics is a biotechnology company focused on creating unique products to address the medical needs of patients with chronic illnesses.

Dec 17, 2024 · The transplant is the fourth xenotransplant using United Therapeutics’ xeno organs into living humans, following two successful UHeart transplants at the University of Maryland Medicine in 2022 and 2023 and a successful UThymoKidney transplant at NYU Langone Health earlier this year.

United Therapeutics (Nasdaq: UTHR) seeks to travel down the corridors of indifference to develop treatments for rare, deadly diseases. We were founded in 1996 by a family seeking a cure for their daughter’s pulmonary arterial hypertension, or PAH.